Drug intelligence / Profile preview

DNZ-35A

Development stage: Preclinical

Overview

DNZ-35A is an **experimental anti-cancer agent** whose specific mechanism of action and molecular target have not been fully characterized in publicly available sources. In preclinical settings, it has been evaluated for its effect on **tumor growth and animal body weight**. Data indicate that the DNZ-35A-treated group showed an overall increase in body weight and a reduction in tumor volume, suggesting potential anti-tumor efficacy[1]. Detailed molecular information, precise targets, modality, and the developer are not described in the available literature.

Other names: DNZ-35ADNZ35ADNZ 35A

Targets

BCL-2 (BCL-2 family)

Beyond the preview

Go deeper on DNZ-35A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNZ-35A.

Explore the full profile